ANTHRACYCLINONES. PART VIII.¹ SYNTHESIS OF A 9-METHYL ANTHRACYCLINONE FROM D-GLUCOSE


Brigitte Deguin, Emmanuel Bertounesque, Gilbert Gaudel, Jean-Claude Florent and Claude Monneret*

Service de Chimie, CNRS, URA 1387, Institut Curie, Section de Biologie, 26 rue d'Ulm, 75231 Paris Cedex 05.

(Received in Belgium 20 February 1992)

Abstract : The chiral pool synthesis of enantiomerically pure anthracyclinone 6 from leucoquinizarin 10, and from 3-O-benzyl-1,2-O-isopropylidene-3-C-methyl- α -D-ribo-pentodialdo-1,4-furanose (9) readily obtained from diacetone glucose, is reported.


The clinical efficacy of daunorubicin (or daunomycin) 1 and doxorubicin (or adriamycin) 2 as antitumor agents² has motivated the search for new anthracyclines devoid of their well-known cumulative dose-dependent cardiotoxicity.³ Although a large number of studies have been directed toward the synthesis of aglycones closely related to daunomycinone, only a limited number of asymmetric syntheses have been reported.⁴ For our part, we have been engaged in a broad program to develop the chiral pool synthesis of new aglycone moieties and, as a result, aglycones 3 and 4 were obtained from α -D-isosaccharinolactone^{1,5} and, more recently, aglycones 5 and 6 from α -D-glucosaccharino-1,4- lactone.⁶



**Dedicated to Professor Gabor Fodor on the occasion of his 75th birthday

Recent reports have shown that 9-alkyl anthracyclines⁷ and in particular, 9-alkyl anthracyclines combined with a 3'-morpholino-3'-deamino daunosaminyl (or 2,3,6-trideoxy-3-morpholino-L-*lyxo*-hexopyranosyl) moiety exhibit high antitumor activity even against a number of doxorubicin-resistant cell lines.⁸ This has prompted us to search for a versatile synthon for the synthesis of various 9-alkyl aglycones. Commercially available diacetone glucose seemed to be the most suitable and in this paper ⁹ we report in detail the synthesis of the 9-methyl anthracyclinone **6** from **7**.


The starting material, 3-O-benzyl-3-C-methyl-1,2:5,6-di-O-isopropylidene- α -D-glucofuranose 7 was readily obtained from diacetone-glucose according to Brimacombe *et al*¹⁰ and Funabashi *et al*.¹¹ This branched -chain sugar was then converted (Scheme 1) into the corresponding mono-isopropylidene derivative **8**,



Reagents and conditions. (a) aq. 75% AcOH, H₂O, r.t., 18 h (b) NaIO₄, H₂O,MeOH, r.t. 15h (c) DBU, DMF, r.t. 5 min (d) Na₂S₂O₄. DMF, 80°C, H₂O, 30 min (e) 75% AcOH, reflux, 10 h (f) 1/ NaIO₄, H₂O, THF, 3 h 2/ MeOH, THF, KOH,Na₂S₂O₄, r.t., 12 h (g) Na₂S₂O₄, H₂O, 30 min (h) BBr₃, CH₂Cl₂, - 78°C, 1h --> r.t. 1h (i)c. α - Dimethoxypropane, CSA, DMF, r.t., 18h.

SCHEME 1.


using 75% aqueous acetic acid. The aldehyde 9 was subsequently prepared by treatment of 8 with sodium metaperiodate. On reacting 9 with leucoquinizarin 10 under Shaw conditions¹² (DBU in DMF), the alkylanthraquinone 11 was isolated in 82% yield as a mixture of diastereoisomers in a 1.5:1 ratio as determined by NMR spectroscopy. Both diastereoisomers 11a and 11b could be isolated as pure compounds by column chromatography with toluene-acetone (98:2) as eluent and the C-5 configuration of these diastereoisomers was assigned by comparison with literature data.¹³ Removal of the benzylic OH was achieved on heating 11 in dry DMF in the presence of sodium dithionite to give 12 in 76% yield. Alternatively, alkylanthraquinone 12 could be readily prepared in 61% yield by condensation of 9 with leucoquinizarin under Lewis conditions¹⁴ (piperidinium acetate for 24 h at room temperature). Conversion of 12 into the corresponding diol 13 was carried out (60% yield) by treatment with 75% aqueous acetic acid. Intermediate 13 was subsequently converted to a mixture of 15 (45%) and 16 (25%) of (10S) and (10R) configuration, respectively, by the following sequence of reactions: sodium metaperiodate cleavage, alkaline deformylation of the intermediate species and, intramolecular aldolisation under Marschalk conditions¹⁵ (KOH and sodium dithionite). Configurations at C-10 were deduced from examination of the CD spectra of 15 and 16. Thus, the 10R configuration of 16 was unequivocally assigned by comparison of its CD curve with the curve of γ -rhodomycinone¹⁶ as shown in Figure 2. The almost opposite CD curve obtained for 15 correlated with the corresponding S configuration at C-10.1



Circular dichroism of compounds 15 and 16

Benzylic deoxygenation of both diastereoisomers using sodium dithionite in THF gave 17 in only 30% yield along with the formation of side-products including fully aromatized 18 (20%) and unsaturated compound 19 (30%). Better results were observed when DMF was used as the solvent. Under these conditions 17 was isolated in 78% yield with only a small amount of 19 (15%). Treatment of 17 with boron tribromide in dichloromethane at -78°C provided the anthracyclinone 6 (75%) whereas further treatment with α,α -dimethoxypropane in the presence of camphorsulfonic acid gave 20 (72%). Compounds 6 and 20 were fully correlated (m.p., $[\alpha]_D$ and spectral data) with the (-)-(8R,9S)-7,8,9,10-tetrahydro-6,8,9,11-tetrahydroxy-9-methyl-5,12-naphthacene quinone and its corresponding isopropylidene derivative, respectively, already obtained⁶ from glucosaccharino-1,4-lactone.¹⁷.

Having thus secured the stereochemical identity of aglycon 6, several options were considered for the manipulation of the 8-OH group *en route* to the required (8R,9S) intermediate aglycon (scheme 2), bearing a 9-amino function (type A). This compound bears a direct relation to the two aglycons of highly antitumor anthracyclines, 9-amino-9-deoxy daunomycinone¹⁸ (type B), and (8S)-methoxy daunomycinone¹⁹(type C). This will be reported later on.



EXPERIMENTAL SECTION

Melting points were determined using a Reichert Thermovar apparatus and are uncorrected. IR spectra were determined on a Perkin-Elmer Model 1710 and ¹H NMR spectra on a spectrophotometer Bruker (270MHz) using TMS as an internal standard. Mass spectra were registered on a Nermag R10.10C (DCI/NH₃) spectrometer. Optical rotations were determined with a Perkin-Elmer 241 polarimeter and circular dichroism with a Jobin-Yvon Mark V apparatus. Flash chromatographies²⁰ were performed on Merck silica gel 60 (Art. 9385). Elemental analyses were carried out at the "Service Central de Micronanalyse du CNRS".

3-O-Benzyl-3-C-methyl-1,2-O-isopropylidene-α-D-allofuranose (8).

Branched-chain sugar 7^{11} (800 mg, 2.2 mmol) was stirred overnight in aqueous acetic acid (75%, 20 mL). After evaporation under reduced pressure, followed by co-evaporations with toluene (2x 20 mL), a flash-chromatography with hexane-acetone (2:1) as eluent gave **8** (680 mg, 95%) as a crystalline compound mp 117°C (lit.¹⁰ mp 119-120°C from EtOH); $[\alpha]_D^{20} + 44^\circ$ (c 1, chloroform); IR (CHCl3): v 3500 and 1380cm⁻¹; ¹H-NMR δ 7.36-7.31 (m, 5H, CH₂Bn), 5.75 (d, 1H, J=3.5 Hz, 1-H), 4.70 and 4.60 (2d, 2x1H,

3-O-Benzyl-1,2-O-isopropylidene-3-C-methyl-α-D-ribopentodialdo-1,4-furanose (9).

To a methanolic solution of **8** (500 mg, 1.54 mmol in 10 mL), an aqueous solution of sodium metaperiodate (363 mg, 1.69 mmol in 10 mL) was added dropwise. After stirring at room temperature for 15 min, the mixture was filtered and the filtrate was extracted with EtOAc. Usual work-up quantitatively afforded **9** (450 mg) as crystals mp 40°C (petroleum ether); lit.¹² mp 40°C; $[\alpha]_D^{20} + 71^\circ$ (c 0.9, chloroform); IR (CHCl₃) 1740, 1600 and 1320cm⁻¹; ¹H-NMR δ 9.63 (s, 1H, CHO), 7.62-7.50 (m, 5H, CH₂Bn), 5.26 (d, 1H, J=4.5 Hz, 1-H), 4.61 (s, 2H, CH₂Bn), 4.36 (d, 1H, J=4.5Hz, 2-H), 1.60, 1.36 and 1.25 (3s, 3x3H, Me and CMe₂); MS (DCI/NH₃): *m/z* 310 [M+ NH₄]⁺, 293 [M+ H]⁺, 252 [M+ NH₄- 58]⁺, 235 [M+H -58]⁺, 143, 81.

(5R) and (5S) 3-O-benzyl-1,2-O-isopropylidene-3-C-methyl-5-(9',10'-dihydro-1',4'-dihydroxy-9',10'-dioxo -2'-anthryl)- α -D-ribofuranose (11a) and (11b).

Leucoquinizarin (91 mg, 0.37 mmol) and DBU (0.22 mL, 1.5 mmol) were added to a solution of 9 (100 mg, 0.34 mmol) in dry DMF (20 mL). After 5 min, the solution was reoxidized by bubbling air, diluted with dichloromethane, and 1N HCl was added dropwise until pH 2-3. Separation of the organic layer and usual work-up followed by flash chromatography of the residue with toluene-acetone as eluent (95:5) gave 150 mg of 10 (82%) as a mixture of diastereoisomers. Chromatography on silica gel with toluene-acetone (98:2) allowed to isolate small amounts of each diastereoisomer 11a and 11b, which could be characterized as follows:

Isomer 11a: mp 120-125°C (MeOH); litt.¹² mp 127°C; $[\alpha]D^{20} - 256^{\circ}$ (c 0.1, chloroform)¹³; IR (CHCl₃): v 3620, 1620 and 1590 cm⁻¹; ¹H-NMR: δ 13.49 and 12.89 (2s, 2x 1H, chelated phenols), 8.32 (m, 2H, Ar), 7.82 (m, 2H, Ar), 7.54 (s, 1H, Ar), 7.25-7.13 (m, 5H, CH₂Ph), 5.77 (d, 1H, J=3.5 Hz, 1-H), 5.32 (dd, 1H, J=8, J'=3 Hz, 5-H), 4.62 and 4.56 (2d, 2 x 1H, J=11 Hz, CH₂Ph), 4.39 (d, 1H, J=3.5Hz, 2-H), 4.38 (d, 1H, J=8 Hz, 4-H), 3.34 (d, 1H, J=3 Hz, OH), 1.58, 1.45 and 1.33 (3s, 3x3H, Me and CMe₂); MS (DCI/NH₃) *m/z* 550 [M+ NH₄]⁺, 533 [M+ H]⁺.

Analysis calcd. for C₃₀H₂₈O₉ C, 67.67; H, 5.30. Found C, 67.31; H, 5.36.

Isomer 11b : amorphous solid; $[\alpha]D^{20}$ +160° (c 0.2, chloroform) [litt.¹²:mp 189°C]; IR (CHCl₃): cf. **11a**: ¹H-NMR δ 13.49 and 12.78 (2s, 2 x 1H, chelated phenols), 8.28 (m, 2H, Ar), 7.80 (m, 2H, Ar), 7.46 (s, 1H, Ar), 7.05-7.02 (m, 5H, CH₂Ph), 5.82 (d, 1H, J=3.5 Hz, 1-H), 5.27 (dd, 1H, J=5.5 Hz, 5-H), 4.52 and 4.45 (2d, 2 x 1H, J=11 Hz, CH₂Ph), 4.41 (d, 1H, J=5.5Hz, 4-H), 4.35 (d, 1H, J=3.5 Hz, 2-H), 3.04 (d, 1H, J=6 Hz, OH), 1.57, 1.42 and 1.34 (3s, 3x3H, Me and CMe₂); MS (DCI/NH₃): *m/z* 550 [M+ NH₄]⁺, 533 [M+ H]⁺, 492, 475, 310.

Analysis calcd. for C₃₀H₂₈O₉ C, 67.67; H, 5.30. Found C, 67.36; H, 5.40.

3-O-Benzyl-1,2-O-isopropylidene-3-C-methyl-5-deoxy-5-(quinizarin-2-yl)-α-D-ribofuranose (12).

1) From 11. To a stirred solution of 11 (1.05 g, 1.97 mmol) in dry DMF (25 mL) heated at 80°C, sodium dithionite (500 mg, 2.87 mmol) in water (20 mL) was added under inert atmosphere. The red solution became immediately yellow-brown and, 30 min later, turned to red color. After dilution with water (20 mL), and

extraction with ether (200 mL), flash chromatography with toluene-acetone (95:5) as eluent afforded 740 mg (76%) of 12which crystallized from acetone mp 88-89°C; $[\alpha]_D^{20}$ - 43° (c 0.18, chloroform); IR (CHCl3): v 1625, 1590 and 1375 cm⁻¹; ¹H-NMR: δ (13.89 and 12.87 (2s, 2x 1H, chelated phenols), 8.25 (m, 2H, Ar), 7.74 (m, 2H, Ar), 7.26 (m, 1H, Ar), 5.78 (d, 1H, J=3.8 Hz, 1-H), 4.67 and 4.60 (2d, 2x 1H, J=11Hz, CH₂Bn), 4.47 (dd, 1H, J=10, J'=3.5Hz, 4-H), 4.38 (d, 1H, J=3.8 Hz, 2-H), 3.07 (dd, 1H, J=15, J'=3.5Hz, 5a-H), 2.81 (dd, 1H, J=15, J'=10, 5b-H), 1.59, 1.35 and 1.34 (3s, 3x3H, Me and CMe₂); MS (DCI/NH₃): m/z 534 [M+ NH₄]⁺, 517 [M+ H]⁺, 476, 459.

Analysis calcd. for C30H28O8 C, 69.75; H, 5.46. Found C, 69.83; H, 5.21.

2) From 9 and leucoquinizarin To a degased solution of dry 2-propanol (50 mL), freshly distilled piperidine (18.8 mL, 190 mmol) and acetic acid (5.60 mL, 95 mmol) were added. The mixture was kept under argon atmosphere and cooled to 0°C. After 30 min, a solution of aldehyde 9 (1.77 g, 6.06 mmol) in propanol (40 mL), and a solution of leucoquinizarin (4.60 g, 18.8 mmol) in THF (10 mL) were added. The mixture was allowed to reach room temperature and then kept for 24h with stirring before reoxidation by bubbling air through it, dilution with dichloromethane and acidification by addition of 1N HCl. Separation of the organic layer followed by usual work-up afforded a residue (4g) and flash chromatography (toluene-acetone, 98:2) led to 1.74g (61%) of 12.

3-O-Benzyl-3-C-methyl-5-deoxy-5-(quinizarin-2-yl)-α-D-ribofuranose (13).

A solution of the foregoing compound 12 (470 mg, 0.9 mmol) in 75% aqueous acetic acid (15 mL) was stirred for 10h under reflux. Evaporation of the solvent followed by co-evaporation with toluene (2x 10mL) afforded a red residue, and chromatography on silica gel (toluene-acetone, 95:5) gave 13 (260 mg, 60%) as an amorphous solid: $[\alpha]_D^{20} + 100^{\circ}$ (c 0.2, THF, after equilibrium); IR (CHCl₃): v 3500, 1624 and 1590cm⁻¹; ¹H-NMR (anomeric mixture): δ 13.53, 13.44, 13.43 and 12.88 (4s, total 2H, H-ar), 7.73 and 7.68 (m, total 2H, H-ar), 7.22 (m, 5H, Bn), 7.17 (s, 1H, Ar), 5.24 (m, 1H, 1-H), 4.70-4.33 (m, 3H, <u>CH2</u>Bn and 4-H), 4.06 (d, 1H, exch. D₂O, J=10Hz, OH), 3.74 (m, 1H, 2-H), 3.13 (dd, 1H, J=14, J'=4 Hz, 5a-H), 2.95 (d, 1H, exch. D₂O, J=4Hz, OH), 2.60 (dd, 1H, J=14, J'=10Hz, 5b-H), 1.53 and 1.26 (2s, total 3H, 5-CH3); MS (DCI/NH3): m/z 494 [M+ NH4]⁺, 476 [M+ NH4-H₂O]⁺, 459.

(8R,9R,10S)-9-O-Benzyl-7,8,9,10-tetrahydro-6,8,9,10,11-pentahydroxy-9-methyl-5, 12 naphthacenequinone (15) and its (8R,9R,10R)- diastereoisomer (16)

Sodium metaperiodate (3.12 g) in water (40 mL) was added to a solution of 13 (3.5 g, 7.35 mmol) in 60 mL of THF. After stirring for 3 h at room temperature, extraction with EtOAc (300 mL) and evaporation under reduced pressure afforded a crude residue which was dissolved in a mixture of MeOH and THF (7/1, 100 mL). Addition of an aqueous solution of KOH (1.52 g in 35 mL) was followed, after stirring for 30 min at room temperature, by addition of sodium dithionite (1.1 g, 6.32 mmol) in 17 mL of water. Stirring was maintained for 12 h at room temperature and for 30 min, after a new amount of sodium dithionite (1.1 g, 6.32 mmol) had been added. Subsequent addition of 1N NaOH (coloration becoming purple), reoxidation by bubbling air through the reaction mixture, neutralization with 1N HCl and extraction with EtOAc (3x 500 mL) led to 3 g of crude red residue. Chromatography on silica gel with toluene-acetone (90:10) gave successively 15 (1.64 g, 45%) and 16 (1.08 g, 25%).

Isomer 15 mp 252-254°C (MeOH); $[\alpha]_D^{20}$ - 210° (c 0.1, chloroform); ¹H-NMR: δ 13.68 and 13.40 (2s, 2 x 1H, chelated phenols), 8.36 (m, 2H, Ar), 7.82 (m, 2H, Ar), 7.52-7.35 (m, 5H, Ar), 5.22 (br s, J=1 Hz,

10-H), 4.98 and 4.82 (2d, 2 x 1H, J=10 Hz, CH₂Bn), 4.35 (m, 1H, 8-H), 3.84 (d, 1H, J=10Hz, OH), 3.52 (dd, 1H, J=20, J'=3 Hz, 7a-H), 3.00 (dd, 1H, J=20, J'=5.5Hz, 7b-H), 1.30 (s, 3H, 9-CH₃); MS (DCI/NH₃): m/z 464 [M+ NH₄]⁺, 447 [M+ H]⁺, 429, 411.

Analysis calcd. for C₂₆H₂₂O₇ (446.19) C, 69.94; H, 4.96. Found C, 69.93; H, 5.16.

Isomer 16 mp 210-212°C (MeOH-THF); $[\alpha]_D^{20}$ - 32° (c 0.1, chloroform); ¹H-NMR: δ 13.80 and 13.30 (2s, 2 x 1H, chelated phenols), 8.35 (m, 2H, Ar), 7.82 (m, 2H, Ar), 7.25 (m, 5H, Ar), 5.32 (d, 1H, J=3 Hz, 10-H), 4.75 (s, 2H, <u>CH</u>₂Bn), 4.22 (ddd, 1H, J=J'=7, J"=6Hz, 8-H), 3.50 (d, 1H, disp. D₂O, J=3Hz, 10-OH), 3.22 (dd, 1H, J=18, J'=6Hz, 7a-H), 3.05 (dd, 1H, J=18, J'=7Hz, 7b-H), 2.35 (d, 1H, disp. D₂O, J=7Hz, 8-OH), 1.30 (s, 3H, 9-CH₃); MS (DCI/NH₃): m/z 447 [M+H]⁺.

Analysis calcd. for C₂₂H₂₂O₇ C, 69.94; H, 4.96. Found C, 70.20; H, 5.19.

(8R,9S)-9-O-Benzyl-7,8,9,10-tetrahydro-6,8,9,10,11-pentahydroxy-9-methyl-5,12 naphthacene quinone (17).

a) By reduction of 15 (or 16) with sodium dithionite in THF.

Compound 15 (or compound 16) (100 mg, 0.22 mmol) was dissolved in dry THF (20 mL) in the presence of sodium dithionite (200 mg, 1.37 mmol) dissolved in water (25 mL). The mixture was stirred for 30 min, whereas bubbling of argon was maintained during the reaction. After work-up, flash chromatography with toluene, toluene-acetone (90:10) led to 18 (20 mg, 20%), 19 (30 mg, 30%), and to 17 (30 mg, 30%).

b) by reduction of 15 (or 16) with sodium dithionite in DMF.

Compound 15 (or compound 16) (400 mg, 0.89 mmol) was dissolved in dry DMF (30 mL) and treated as above with sodium dithionite (830 mg, 2.18 mmol) in water (15 mL). The mixture was treated as above and flash chromatography led to 19 (60 mg, 15%) then to 17 (300 mg, 78%).

Compound 17 : mp 187-188°C (MeOH); $[\alpha]_D^{20}$ - 54° (c 0.12, chloroform) and - 32° (c 0.12, THF); IR (CHCl₃): v 1623 and 1589cm⁻¹; ¹H-NMR: δ 13.45 and 13.32 (2s, 2 x 1H, chelated phenols), 8.30 (m, 2H, Ar), 7.79 (m, 2H, Ar), 7.25 (s, 5H, Ar), 4.68 (s, 2H, <u>CH2</u>Bn), 4.02 (dd, 1H, J=J'=4Hz, 8-H), 3.13 and 2.92 (2 dd, 2x 1H, J=18, J'=4Hz, 7-H), 3.08 and 2.96 (2d, 2x 1H, J=18Hz, 10-H), 1.30 (s, 3H, 9-CH₃); MS (DCI/NH₃): *m/z* 448 [M+ NH₄]⁺, 431 [M+ H]⁺, 430 [M+ NH₄-H₂O]⁺.

Analysis calcd. for C₂₆H₂₂O₆ C, 72.52; H, 5.15. Found C, 72.72; H, 5.20.

9,10-Dihydro-6,8,11-trihydroxy-9-methyl-5,12-naphthacene dione (19) 21

Amorphous solid; $[\alpha]_D^{20} - 137^\circ$ (c 0.12, CHCl₃); IR (KBr): v 1620 and 1585cm⁻¹; ¹H-NMR: δ 13.46 and 13.34 (2s, 2x 1H, chelated phenols), 8.28 (m, 2H, Ar), 7.83 (m, 2H, Ar), 6.85 (d, 1H, J=1Hz, 10-H), 4.67 (dd, 1H, 8-H), 3.42 (d, 1H) and 2.93 (d, 1H, CH₂-7), 2.10 (d, 3H, J=1Hz, 9-CH₃); MS (DIE): m/z 322 [M⁺, 70%], 307 [M⁺-- 15, 50%), 304 [M⁺--18, 55%], 279.

Analysis calcd. for C19H14NO5 (322.32) C, 70.80; H, 4.37. Found C, 70.85; H, 4.30.

(8S,9R)-7,8,9,10-Tetrahydro-6,8,9,11-tetrahydroxy-9-methyl-5,12-naphthacene quinone (6)

A solution of 17 (760 mg, 1.76 mmol) in dry CH_2Cl_2 (300 mL) was treated at -78°C under N₂ with a solution of BBr₃ in CH₂Cl₂ (1M, 5.3 mL). The mixture, which became purple, was stirred for 1h at room temperature, treated with aqueous NaHCO₃, and extracted with CH₂Cl₂. Usual work-up gave a crude residue (580 mg) and flash chromatography with toluene, and then toluene-acetone (70/30) provided 450 mg (75%) of

6 as a crystalline compound mp 254°C; [α]_D²⁰ -18° (c 0.1, dioxane); [lit.⁶ mp 255-257°C; [α]_D²⁰ - 27° (C 0.14, dioxane)]; $[\alpha]_{\Omega}^{20}$ - 20° (c 0.1, MeOH).

(8R,9S)-7,8,9,10-Tetrahydro-6,8,9,11-tetrahydroxy-8,9-O-isopropylidene-9-methyl-5,12-naphthacene quinone (20)

To a solution of 6 (50 mg, 0.14 mmol), in dry DMF (3 mL) were added α, α -dimethoxypropane (0.12 mL), and camphorsulfonic acid (5 mg) as catalyst. After stirring overnight at room temperature under inert atmosphere. extraction with ethyl acetate and neutralization with aqueous NaHCO3, afforded 53 mg (95%) of 20. Crystallization from MeOH gave mp 213-214°C; $[\alpha]_{D}^{20}$ +88° (c 0.1, chloroform); [Lit 6 mp 210-213°C] (MeOH); $[\alpha]_D^{20}$ +89° (c 0.25, chloroform)]; ¹H-NMR spectrum was in full agreement with that previously reported⁶.

Acknowledgements: For financial support of this work, we thank the CNRS (URA 1387) and Laboratories Hoechst-France. We gratefully acknowledge Prof. G. Shaw for providing us a sample of compound 11a (see ref. 13) and Dr J. Bolard (URA 198) for recording circular dichroism.

Réferences and Notes:

- For part VII see: Bertounesque, E; Florent, J.-C.; Monneret, C. Synthesis 1991, 270-272. 1.
- 2. Arcamone, F. Doxorubicin Anticancer Antibiotics, Academic Press, New-York, 1981.
- 3. Bonadonna, G.; Monfardini, S. Lancet, 1969, 837; Lenaz, L; Page, J.A. Cancer Treatment Rev., **1976,** 3, 111- 120.
- 4. Naruta. Y.: Nishigaichi, Y.: Maruyama, K. J. Chem. Soc. Perkin Trans 1, 1991, 831-838 and references cited therein.
- 5. a: Bennani, F.; Florent, J.-C.; Koch, M.; Monneret, C. Tetrahedron Letters, 1984, 25, 3975-3978; b: Tetrahedron, 1984, 40, 4669-4676; c: Florent, J.-C.; Genot, A.; Monneret, C. Tetrahedron Letters, 1985, 26, 5295-5298; d: Florent, J.-C.; Ughetto-Monfrin, J.; Monneret, C. J. Org. Chem., 1987, 52, 1051-1056; e: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 52, 1057-1063; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 52, 1057-1063; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 52, 1057-1063; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 52, 1057-1063; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 52, 1057-1063; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 52, 1057-1063; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 52, 1057-1063; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 52, 1057-1063; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 52, 1057-1063; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 52, 1057-1063; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 52, 1057-1063; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 52, 1057-1063; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 52, 1057-1063; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1989, 30, 711-714; g: Bertounesque, 1057-1063; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 50, 711-714; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1989, 30, 711-714; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1989, 30, 711-714; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1988, 90, 711-714; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 72, 700; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 72, 700; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 72, 700; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 72, 700; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 72, 700; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., 1987, 72, 700; f: Genot, A.; Florent, J.-C.; Monneret, C. J. Org. Chem., E.; Florent, J.- C.; Monneret, C. Tetrahedron Letters, **1990**, 31, 7153-7156. Deguin, B.; Florent, J.- C.; Monneret, C.J. Org.Chem., **1991**, 56, 405-411. Scott, C.A.; Wesmacott, D.; Broadhurst, M.J.; Thomas, J.; Hall, M.J. Br. J. Cancer, **1986**, 53,
- 6.
- 7. 595-600.
- De Vries, E.G.E.; Zijlstra, J.G. Eur. J. Cancer, 1986, 26, 659-660; Coley, H.M.; Twentyman, P.R.; 8. Morkman, P. Ibid, 665-667.
- Deguin, B. Ph.D. dissertation, Université Paris VI, 1990. 9.
- 10. Brimacombe, J.S.; Rollins, A.J.; Thompson, S.W. Carbohydr. Res., 1973, 31, 108-113.
- 11. Funabashi, M.; Yamazaki, S.; Yoshimura, Carbohydr. Res., 1975, 44, 275-283.
- 12. Ali, Z.; Qureshi, S., Shaw, G.; De Clercq, E. J. Chem. Soc., Perkin Trans I, 1990, 2627-2636, and references cited therein.
- 13. From sample provided by Prof. G. Shaw: (α)_D²⁰ 255° (c 0.2, CHCl₃); ¹H NMR superimposable.
- Lewis, C.E. J. Org. Chem., 1970, 35, 2938-2942
 Marschalk, C.; Koenig, F.; Ourousoff, N. Bull. Soc; Chim. Fr., 1936, 1545-1575.
 Brockmann, H., Jr; Legrand, M. Tetrahedron, 1963, 19, 395.
- 17. It is important to note that in the closely related synthesis reported by Shaw et al.¹² the configuration at C-8 and C-9 in compounds 19a-k given by these authors do not correspond to that determined by us for compounds 6 and 20. The structures for compounds 19a-k may, therefore, require revision.
- Ishizumi, K.; Ohashi, N.; Tanno, N.J. Org. Chem., 1987, 52, 4477-4485.
 Naff, M.B.; Plowman, J.; Narayanan, V.L. Anthracyclines in the National Cancer Institut Program. In Anthracycline Antibiotics, El Khadem, H.S., Ed; Academic Press New-York, 1982 pp. 1-57.
- 20. Still, W.C.; Kahn, M.; Mitra, A.J. Org. Chem., 1978, 43, 2923-2925.
- 21. Confalone, P.N.; Pizzolato, G. J. Org. Chem., 1990, 55, 5520-5525.